2006
The Nonimpact of the Expanded Syringe Access Program upon Heroin Use, Injection Behaviours, and Crime Indicators in New York City and State
Johnson B, Golub A, Deren S, Jarlais D, Fuller C, Vlahov D. The Nonimpact of the Expanded Syringe Access Program upon Heroin Use, Injection Behaviours, and Crime Indicators in New York City and State. Justice Research And Policy 2006, 8: 27-49. DOI: 10.3818/jrp.8.1.2006.27.Peer-Reviewed Original ResearchSyringe access programsHeroin useDrug usersAccess programInjection drug usersBlood-borne diseasesHealth care providersIllicit drug usersExpanded Syringe Access ProgramHepatitis C.Drug injectionDrug treatmentCare providersClean syringesSyringe accessSubstance abuseNew York StateLarger evaluationSyringesInjection behaviorNew York CityHIVYork CityDisease
1992
Effect of Chronic Substance Abuse on the Neuropsychological Performance of Intravenous Drug Users with a High Prevalence of HIV-1 Seropositivity
Concha M, Graham N, Muñoz A, Vlahov D, Royal W, Updike M, Nance-Sproson T, Seines O, McArthur J. Effect of Chronic Substance Abuse on the Neuropsychological Performance of Intravenous Drug Users with a High Prevalence of HIV-1 Seropositivity. American Journal Of Epidemiology 1992, 136: 1338-1348. PMID: 1362630, DOI: 10.1093/oxfordjournals.aje.a116446.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsBaltimoreBlack or African AmericanCD4-Positive T-LymphocytesChronic DiseaseCognition DisordersConfounding Factors, EpidemiologicEducational StatusEmploymentEvaluation Studies as TopicFemaleHIV SeropositivityHIV SeroprevalenceHIV-1HumansLeukocyte CountLinear ModelsMaleMass ScreeningNeuropsychological TestsPopulation SurveillancePredictive Value of TestsPrisonsPsychomotor PerformanceSubstance Abuse, IntravenousConceptsNeuropsychological test performanceHIV-1 seropositivityIntravenous drug usersTest performanceNeuropsychological performancePractice effectsHuman immunodeficiency virus type 1 (HIV-1) infectionDrug usersVirus type 1 infectionSubstance abuseSignificant practice effectsHIV-1 serostatusType 1 infectionIntravenous Experience (ALIVE) studyFrequency of drugChronic substance abuseNeuropsychological functioningCognitive performanceImmunodeficiency syndromeAsymptomatic stageHigh prevalenceOutcome measuresDrug useIntoxicated individualsMultivariate analysis